This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03640481
Recruitment Status : Terminated (The sponsor has decided to prematurely terminate the study due to the challenges encountered in recruiting adolescent participants. This decision was made without any safety concerns.)
First Posted : August 21, 2018
Last Update Posted : December 21, 2023
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Kadmon, a Sanofi Company )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy

Condition or disease Intervention/treatment Phase
Chronic Graft-versus-host-disease Drug: Belumosudil (KD025) Phase 2

Detailed Description:

Phase 2, open label, randomized, multicenter study in subjects with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy. Approximately 166 subjects with active cGVHD will be randomized (1:1) to receive treatment with one of two belumosudil (formerly known as KD025) regimens:

  • Arm A: belumosudil 200 mg QD
  • Arm B: belumosudil 200 mg BID

With Amendment 2, the sample size was increased from approximately 126 subjects, with additional subjects to be enrolled as follows:

  • 20 adolescents
  • 20 adults into a site-specific Companion Study to collect biospecimens

These additional subjects will also be randomized (1:1) to Arm A or Arm B.

Any adolescent taking a proton pump inhibitor (PPI) or a strong CYP3A4 inducer will begin Cycle 1 Day 1 at the escalated dose of belumosudil 200 mg BID.

Randomization will be stratified according to prior cGVHD treatment with ibrutinib (Yes / No) and severe cGVHD at baseline (Yes / No). Subjects may receive treatment in 28-day treatment cycles until clinically significant progression of cGVHD. Subjects who have not achieved a response after 12 cycles of belumosudil should be withdrawn if in the Investigator's judgment there is no evidence of clinical benefit. Subjects will undergo evaluations as outlined in the Study Assessments table (Appendix A). The primary endpoint is the overall response rate (ORR) with responses as defined by the 2014 National Institute of Health (NIH) Consensus Development Project on clinical trials in cGVHD.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 159 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase 2, open label, randomized, multicenter study in subjects with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Actual Study Start Date : October 11, 2018
Actual Primary Completion Date : December 11, 2023
Actual Study Completion Date : December 11, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Belumosudil

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A: belumosudil 200 mg QD
Eligible subjects randomized to arm A will take belumosudil 200 mg once daily
 Drug: Belumosudil (KD025)
Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Other Name: REZUROCK
Experimental: Arm B: belumosudil 200 mg BID
Eligible subjects randomized to arm B will take belumosudil 200 mg twice daily
 Drug: Belumosudil (KD025)
Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Other Name: REZUROCK


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: up to approximately 40 months ]
    The primary endpoint is the ORR with responses as defined by the 2014 National Institute of Health (NIH) Consensus Development Project on clinical trials in cGVHD.


Secondary Outcome Measures :
  1. Duration of Response (DOR) [ Time Frame: up to approximately 40 months ]
    The time from initial response of PR or CR until documented progression of cGVHD

  2. Change in Lee Symptom Scale Score [ Time Frame: up to approximately 40 months ]
    Analyses will include: Number of subjects with a ≥7 point reduction, Number of subjects with a ≥7 point reduction on 2 consecutive assessments and Duration of a ≥7 point reduction. Symptom burden will be assessed on Day 1 of each cycle starting on Cycle 1 Day 1, as well as at the EOT visit. The questionnaire asks subjects to indicate the degree of bother that they experienced due to symptoms in seven domains potentially affected by chronic GVHD (skin, eyes, mouth, breathing, eating and digestion, energy, and emotional distress). The response will be determined based on clinician assessment specifically for each of affected organ as a Complete Response, Partial Response or Progression.

  3. Response rate by organ system [ Time Frame: up to approximately 40 months ]
    The response assessment for the nine individual organs (Skin, Eyes, Mouth, Esophagus, Upper GI, Lower GI, Liver, Lungs, and Joints and fascia).

  4. Percentage of subjects who have a best response of PR or CR [ Time Frame: up to approximately 40 months ]
  5. Change in corticosteroid dose [ Time Frame: up to approximately 40 months ]
  6. Change in calcineurin inhibitor dose [ Time Frame: up to approximately 40 months ]
  7. Failure-free survival (FFS) [ Time Frame: up to approximately 7 years ]
    FFS is defined as the absence of cGVHD treatment change, non-relapse mortality and recurrent malignancy. Median FFS (from first dose of belumosudil) and landmark FFS at 1 year will be analyzed.

  8. Overall Survival (OS) [ Time Frame: up to approximately 7 years ]
    Time from first dose of belumosudil to the date of death due to any cause.

  9. Change in cGVHD severity as based on the Physician-reported global cGVHD Activity Assessment [ Time Frame: up to approximately 40 months ]
    Physician-reported outcome

  10. Change in symptom activity as based on cGVHD Activity Assessment Patient Self-Report [ Time Frame: up to approximately 40 months ]
    Patient-reported outcome

  11. Determine the Peak Plasma Concentration (Cmax) of belumosudil [ Time Frame: Pre-dose and post-dose sampling within 12 hours ]
    Determine the maximum plasma concentration (Cmax) of belumosudil

  12. Determine the observed time to reach peak plasma concentration (Tmax) of belumosudil [ Time Frame: Pre-dose and post-dose sampling within 12 hours ]
    The time that belumosudil reach the maximum plasma concentration (Tmax).

  13. Determine the half-life (T1/2) of belumosudil [ Time Frame: Pre-dose and post-dose sampling within 12 hours ]
    The time it takes for half of belumosudil to be removed from plasma by biological processes (T1/2)

  14. Determine the area under the plasma concentration versus time curve (AUC) of belumosudil [ Time Frame: Pre-dose and post-dose sampling within 12 hours ]
    Area under the plasma concentration versus time curve (AUC)

  15. Time to Response [ Time Frame: up to approximately 40 months ]
    The time it takes to obtain a cGVHD response to belumosudil.

  16. Time to next treatment [ Time Frame: up to approximately 40 months ]
    The time it takes to initiate a new systemic cGVHD treatment after starting belumosudil.

  17. Number pf participants with adverse event and serious adverse events [ Time Frame: Up to 28 days after the last dose of study treatment i.e., up to approximately 7 years ]
    Safety will be assessed by monitoring adverse events, clinical laboratory evaluations, vital sign measurements, and ECG parameters.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects at least 12 years of age who have had allogenic hematopoietic cell transplant (HCT).
  2. Previously received at least 2 and not more than 5 lines of systemic therapy for cGVHD
  3. Receiving glucocorticoid therapy with a stable dose over the 2 weeks prior to screening
  4. Have persistent cGVHD manifestations and systemic therapy is indicated
  5. Karnofsky Performance Score of ≥ 60 (if aged 16 years or older); Lansky Performance Score of ≥ 60 (if aged < 16 years)
  6. Weight ≥ 40kg

Exclusion Criteria:

  1. Subjects has not been on a stable dose / regimen of systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin inhibitors, sirolimus, MMF, methotrexate, rituximab, and extracorporeal photophoresis (ECP) are acceptable. Systemic investigational GVHD treatments are not permitted).
  2. Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
  3. Current treatment with ibrutinib. Prior treatment with ibrutinib is allowed with a washout of at least 28 days prior to randomization.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03640481


Locations
Show Show 39 study locations
Sponsors and Collaborators
Kadmon, a Sanofi Company
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Kadmon, a Sanofi Company
ClinicalTrials.gov Identifier: NCT03640481    
Other Study ID Numbers: DRI17633
KD025-213 ( Other Identifier: Kadmon )
U1111-1279-2518 ( Registry Identifier: ICTRP )
First Posted: August 21, 2018    Key Record Dates
Last Update Posted: December 21, 2023
Last Verified: December 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiolitis Obliterans Syndrome
Graft vs Host Disease
Immune System Diseases
Organizing Pneumonia
Bronchiolitis Obliterans
Bronchiolitis
Bronchitis
Bronchial Diseases
 Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Belumosudil
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action